LAVA Therapeutics NV is an immuno-oncology company, which engages in the proprietary Gammabody platform to develop a portfolio of bispecific gamma delta T cell engagers for the potential treatment of solid tumors and hematological malignancies. The company was founded by Erik van den Berg in 2016 and is headquartered in Utrecht, the Netherlands.
相关临床试验
2
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2016
终止
2
100.0%
暂无批准数据
- Xoma Royalty has agreed to acquire Generation Bio, a struggling gene therapy developer, for approximately $4.29 per share in its latest "zombie biotech" acquisition. - Generation Bio raised $200 million in its 2020 IPO to develop lipid nanoparticle-based gene therapy technology but faced setbacks including disappointing preclinical results and workforce reductions. - The acquisition includes contingent value rights for shareholders, potentially providing additional payments from cash holdings, lease savings, Moderna partnership milestones, and proceeds from delivery technology sales. - Generation Bio recently slashed 90% of its workforce and began strategic review after touting RNA delivery technology for T cells, fitting Xoma's pattern of acquiring distressed biotech companies.
- XOMA Royalty Corporation reported robust financial performance in Q3 2025, receiving $43.9 million in royalties and milestones from partners in the first nine months of 2025, including $14.3 million in Q3 royalties. - The company completed strategic acquisitions of Turnstone Biologics and HilleVax while announcing planned acquisitions of LAVA Therapeutics and Mural Oncology to expand its royalty portfolio. - Key pipeline developments include Zevra Therapeutics submitting a Marketing Authorization Application to the EMA for arimoclomol in Niemann-Pick Type C disease and Rezolute Bio expecting Phase 3 ersodetug trial results in December 2025. - XOMA Royalty achieved net income of $14.1 million in Q3 2025 compared to a net loss of $17.2 million in the same period of 2024, demonstrating improved operational performance.
- Xoma Royalty Corp. agreed to acquire Mural Oncology for $2.035-2.240 per share, valuing the deal at $35.2-38.8 million depending on closing cash balance. - The acquisition follows Mural's discontinuation of lead IL-2 therapy nemvaleukin alfa after failed Artistry-6 and 7 trials, leading to 90% workforce reduction in April. - Xoma will wind down Mural's operations as part of a growing trend where investment firms acquire struggling biotechs trading below cash value for liquidation. - The deal represents Xoma's fourth oncology acquisition this year, following purchases of Turnstone Biologics, Lava Therapeutics, and HilleVax.
- Xoma Royalty Corporation announced dual acquisitions of HilleVax and Lava Therapeutics, both companies that have struggled significantly since their public debuts several years ago. - HilleVax's value plummeted after a mid-stage trial showed its norovirus vaccine was ineffective, leading to program termination and 40% staff cuts. - Lava Therapeutics, which develops gamma delta T cell engager bispecific antibodies for cancer, laid off 30% of staff following disappointing clinical results. - Both acquisitions represent examples of "biotech zombie" companies trading below their cash holdings, highlighting a growing trend of distressed biotech consolidation.
- Commit Biologics has established a Scientific Advisory Board co-chaired by antibody expert Janine Schuurman and CEO Mikkel Wandahl Pedersen to guide development of its BiCE™ complement activation platform. - The board includes five industry veterans with expertise in molecular biology, immunology, and antibody research, including former executives from Genmab, Regeneron, and Novo Nordisk. - The BiCE™ technology platform aims to harness the largely untapped complement system to selectively kill target cells in autoimmune diseases and cancer through enhanced C1q engagement. - This strategic move positions Commit to accelerate development of first-in-class complement engager therapeutics by leveraging decades of combined industry experience from the advisory members.
• LAVA Therapeutics is implementing significant restructuring, including a 30% workforce reduction and closure of Netherlands operations, while evaluating strategic alternatives to maximize shareholder value. • The company continues to advance its LAVA-1266 Phase 1 trial for CD123+ hematological malignancies, alongside partnered programs with Johnson & Johnson and Pfizer that are also in Phase 1 clinical trials. • With $66.6 million in cash and investments as of March 31, 2025, LAVA expects to fund operations into 2027 despite reporting a net loss of $3.5 million for Q1 2025.
• LAVA Therapeutics has dosed the first patient in a Phase 1 trial of LAVA-1266, a bispecific Gammabody® targeting CD123 for hematological cancers. • The first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of LAVA-1266 in AML and MDS patients. • LAVA-1266 is designed to lyse CD123+ tumor cells with high potency and a wide therapeutic window, potentially overcoming limitations of previous CD123-targeted therapies. • Initial Phase 1 data read-out from the dose escalation study is expected by the end of 2025, marking a key milestone for the company's Gammabody® platform.
